Seraxis

Clinical-stage regenerative medicine company developing islet cell replacement therapy for insulin-dependent (Type 1) diabetes. Lead pipeline asset is a stem-cell-derived islet cell therapy designed to eliminate or significantly reduce the need for daily insulin injections. Pipeline also includes...